Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04038034
Other study ID # VF-GLAU-CoQ10/2019
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2019
Est. completion date August 30, 2021

Study information

Verified date April 2020
Source VISUfarma SpA
Contact Stanislao Rizzo
Phone +39 06 301 54 929
Email stanislao.rizzo@policlinicogemelli.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double blind study with competitive enrolment, aimed to enroll a total of 70 patients with a diagnosis of primary open angle glaucoma (POAG).

Patients, after signing the Informed Consent, will enter into a 1- week screening phase during which the baseline tests will be conducted.

Subjects will be randomized in a 1:1 ratio to the following groups:

- group A of 35 patients treated with pressure lowering drugs and placebo;

- group B of 35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date August 30, 2021
Est. primary completion date August 30, 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion criteria:

- Patient Informed consent form (ICF) signed

- M & F Aged = 40 and = 80 years at the time of the signature of ICF

- Patients with Primary Open Angle Glaucoma (POAG) stage early-moderate according to Hodapp-Parrish-Anderson criteria (MD less than -12 dB)

- Patients must be diagnosed with POAG at least 1 year before the screening visit in this study.

- Anamnesis with at least 1 value of Intraocular pressure (IOP) >21mmHg documented any time prior the initiation of the stable treatment with anti-hypertensive topical drugs.

- Patients affected by POAG and under stable treatment with anti-hypertensive topical drugs in the previous 6 months prior to enrolment to maintain IOP =18 mmHg.

- Corrected visual acuity (using ETDRS tables) = 8/10

- Transparent dioptric means to allow the examination of the OCT >25 µm.

- Pachymetry values between 500 and 600 µm.

- Patients have to show a stable visual field in the previous 6 months prior to enrolment (where by stable visual field it is intended that the patient must remain within the same stage of POAG severity (i.e. early or moderate) during the previous 6 months before the enrolment).

- Willing to follow all study procedures, including attending all site visits, tests and examinations.

- Women must agree to be using two forms of effective contraception, be post-menopausal from at least 12 months prior to trial entry, or surgically sterile.

Exclusion criteria:

- Patients with a severe defect of POAG according to Hodapp-Parrish-Anderson criteria.

- Previously diagnosed optic neuropathies.

- Diabetic retinopathy or Hypertensive retinopathy.

- Decompensated diabetes.

- Not stabilized hypertension (SAP and/or DAP) despite under adequate pharmacological treatment.

- Retinal pathologies including hereditary forms.

- Neurological, neurodegenerative or cerebrovascular conditions.

- No previous history or presence of any disease involving cornea or retina.

- Patients with a significantly progressive opacity of lens in the previous 3 months prior to enrolment (where by significant progressive opacity of lens it is intended patients who have been diagnosed with cataracts of any aetiology and for whom surgery is being considered).

- No surgical intervention for cataract in the previous 3 months prior to enrolment.

- Eye inflammatory conditions (uveitis) diagnosed any time in the patient's history.

- Treatment with topical or systemic neuroprotective agents different from CoQ10. These patients can be admitted in the study after at least a 1 month of wash-out period.

- Treatment with warfarin.

- Treatment with miotic drugs able to influence the visual field.

- Treatment with systemic or topical steroids.

- Refractive defects beyond the 5 spherical diopters, both positive and negative and over 3 cylindrical.

- Any clinically significant history of serious digestive tract, liver, kidney, cardiovascular, cancer or hematological disease.

- Known drug and/or alcohol abuse.

- Mental incapacity that precludes adequate understanding or cooperation.

- Participation in another investigational study or blood donation within 3 months prior to ICF signature.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
CoQ10- MINIACTIVES
COQUN oral formulation 100 mg BID
Placebo
Placebo

Locations

Country Name City State
Italy UO Oculistica - PO Cisanello Pisa PI
Italy U.O. di Oculistica, Fondazione Policlinico Agostino A. Gemelli, Rome

Sponsors (1)

Lead Sponsor Collaborator
VISUfarma SpA

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pattern Electroretinogram Amplitude (PERG P50-N95 A) To evaluate the difference of mean changes of Pattern Electroretinogram Amplitude (PERG P50-N95 A) (µV) observed between the two study groups. between the baseline visit (V0) and the last study visit after 12 months of treatment (V3)
Secondary Pattern Electroretinogram Amplitude (PERG P50-N95 A) To evaluate the difference of mean changes of Pattern Electroretinogram Amplitude (PERG P50-N95 A) (µV) observed between the two study groups. between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Secondary Pattern Electroretinogram Amplitude Implicit Times (PERG P50 IT) To evaluate the changes from baseline to each study visit between the two study groups in Pattern Electroretinogram Amplitude Implicit Times (PERG P50 IT) in milliseconds (ms) between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Secondary Visual Evoked Potentials Implicit Times (VEP P100 IT) To evaluate the changes from baseline to each study visit between the two study groups in Visual Evoked Potentials Implicit Times (VEP P100 IT) in milliseconds (ms) between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Secondary Visual Evoked Potentials Amplitude (VEP N75-P100 A) To evaluate the changes from baseline to each study visit between the two study groups in Visual Evoked Potentials Amplitude (VEP N75-P100 A) in microvolt (µV) between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Secondary Visual field To evaluate the changes from baseline to each study visit between the two study groups in Visual field (separately MD and PSD) evaluated by Humphrey field analyzer (HFA) Sita Standard 30-2 from baseline to each study visit (V1, V2, V3)
Secondary Contrast sensitivity To evaluate the changes from baseline to each study visit between the two study groups in Contrast sensitivity measured with Vistech tables (Vision Chart from CSO) between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Secondary Optical Coherence Tomography To evaluate the changes from baseline to each study visit between the two study groups in Peripapillary retinal nerve fiber layer (RNFL) thickness, macular RNFL, macular ganglion cell layer (GCL), macular inner plexiform layer (IPL) assessed with natural pupils by the means of spectral domain Optical Coherence Tomography (OCT, Heidelberg Spectralis) between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
See also
  Status Clinical Trial Phase
Completed NCT05044793 - A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
Recruiting NCT06201455 - Evaluation of Phacogoniotomy in Medically-controlled POAG N/A
Recruiting NCT03369886 - The Relationship Between Macular OCTA and GCIPL and Their Combinational Index Using AI N/A
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Recruiting NCT02679482 - Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma N/A
Completed NCT02338362 - Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma Phase 4
Active, not recruiting NCT01430923 - Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost N/A
Completed NCT01489670 - Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension N/A
Completed NCT00693485 - Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy Phase 2
Completed NCT00753168 - Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Phase 1/Phase 2
Completed NCT00051194 - A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension Phase 2
Recruiting NCT04920227 - Comparation of CLASS Combined With Phacoemulsification and CLASS Alone in the Treatment of Primary Open Angle Glaucoma N/A
Active, not recruiting NCT03868124 - Clinical Study Comparing Two Models of a Travoprost Intraocular Implant Phase 3
Completed NCT03267862 - Scleral Response to Intraocular Pressure (IOP) N/A
Recruiting NCT06066645 - Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone Phase 3
Recruiting NCT04912362 - The Effectiveness of YAG Iridotomy in Preventing Peripheral Anterior Synechia After CLASS in Primary Open Angle Glaucoma N/A
Completed NCT04949802 - Glaucoma Surgery Using the ViaLase Laser System N/A
Completed NCT04632329 - Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma N/A
Completed NCT01215786 - Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Phase 1
Completed NCT00801437 - Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.